CMS-2P2-25-001: Cell and Gene Therapy (CGT) Access Model
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Center for Medicare and Medicaid Services notices from 2024.
Center for Medicare and Medicaid Services offered grants of up to $9.6 million to state and local governments. It expected to make about 52 awards worth $95.5 million in total. Applications closed on March 14, 2025.
From the official notice on Grants.gov, last changed February 18, 2025. Checked November 7, 2026.
- Award ceiling$9.6 million
- Total funding$95.5 million
- Expected awards52
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | August 15, 2024 |
|---|---|
| Deadline | March 14, 2025 |
| Archived by Grants.gov | March 30, 2025 |
Who can apply
This opportunity was open to state and local governments.
- State governments
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligible applicants are States, the District of Columbia, and any U.S. Territory participating in the Medicaid Drug Rebate Program (MDRP).
Is this a realistic fit?
- Past Cell and Gene Therapy (CGT) Access Model awards averaged $499,750; this notice allows up to $9.6 million per award.
- Most of the program's money (100% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
This Notice of Funding Opportunity (NOFO) announces the opportunity to apply for Cooperative Agreement funding to support States participation in the Cell and Gene Therapy (CGT) Access Model (the CGT Access Model or the Model). Eligible applicants are States, the District of Columbia, and any U.S. territory that participates in the Medicaid Drug Rebate Program (MDRP). A maximum of $9.55 million may be awarded to each Recipient, depending on the number of States that apply for funding, pending availability of funds.
Who has won Cell and Gene Therapy (CGT) Access Model grants before
From fiscal 2021 to 2025, Cell and Gene Therapy (CGT) Access Model (93.885) awarded $4.0 million across 8 grant awards, an average of $499,750 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| PA Department of Human Services | Pennsylvania | 1 | $794,800 |
| Illinois Department of Healthcare & Family Services | Illinois | 1 | $794,800 |
| Department of Social Services Connecticut | Connecticut | 1 | $671,090 |
| Department of Health Care Finance | District of Columbia | 1 | $565,398 |
| North Carolina Department of Health & Human Services | North Carolina | 1 | $558,941 |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CMS-2P2-25-001 still open?
No. It closed on March 14, 2025.
Who can apply for Cell and Gene Therapy (CGT) Access Model?
Center for Medicare and Medicaid Services accepted applications from state and local governments. The notice adds further conditions, so read its eligibility section.
What is the deadline for Cell and Gene Therapy (CGT) Access Model?
Closed March 14, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $9.6 million each. About $95.5 million in total across about 52 awards.
Who has won Cell and Gene Therapy (CGT) Access Model grants before?
The largest recipients over five fiscal years were PA Department of Human Services, Illinois Department of Healthcare & Family Services, Department of Social Services Connecticut. The program made 8 awards worth $4.0 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)